此乃要件 請即處理 閣下如對本通函的任何方面或應採取的行動有任何疑問，應諮詢 閣下的持牌證券商、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已將名下全部烟台北方安德利果汁股份有限公司之股份售出或轉讓，應立即將本通函連 同隨附的代表委任表格轉交予買方或承讓人，或送交經手買賣或轉讓的銀行、持牌證券商或其 他代理商，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 02218 Yantai North Andre Juice Co., Ltd. * ANDRE 二零二四年度利潤分配方案 董事會函件載於本通函第3頁至第5頁。 臨時股東大會將於二零二五年六月十二日（星期四）下午兩時正在中華人民共和國（「中國」）山東 省烟台市牟平區新城大街889號安德利大樓10樓會議室舉行。 臨時股東大會通告以及於該會議上使用的相關代表委任表格已於二零二五年五月二十七日在香 港聯交所網站及本公司網站刊載。 無論 閣下能否出席該會議，務請 閣下根據隨 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任 。 *僅供識別 海外監管公告 本公告乃烟台北方安德利果汁股份有限公司（「本公司」）根據《香港聯合交易所有限公司證券上市 規則》第 13.10B 條作出。 茲載列本公司於二零二五年五月二十七日在上海證券交易所網站刊發之《關於召開 2025 年第一次臨 時股東大會的通知》，僅供參閱。 承董事會命 烟台北方安德利果汁股份有限公司 董事長 王安 中國烟台，二零二五年五月二十七日 於本公告日期，本公司執行董事為王安先生、張輝先生、王萌女士及王艷輝先生，非執行董事為劉宗 宜先生及張偉先生，獨立非執行董事為龔凡先生、王雁女士及王常青先生。 1 证券代码：605198 证券简称：安德利 公告编号：2025-043 烟台北方安德利果汁股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 烟台北方安德利果汁股份有限公司 | | 股份代號 | 02218 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二四年十二月三十一日止年度之末期股息 | | 公告日期 | 2025年5月20日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更新股東批准日期 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 10 股 2.5 RMB | | 股東批准日期 | 2025年6月12日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發 ...

证券代码： 605198 证券简称：安德利 二是产品质量优势：近年来，我国浓缩果汁企业注重技术创新和 质量提升，不断引进先进的生产设备和技术，加强质量控制体系建设。 许多企业通过了国际标准认证，如 ISO9001、HACCP、BRC 等，产品质 量得到国际市场的认可。如安德利公司建立了设施先进的研发实验室 和检测中心，组建了经验丰富的质控检测及新产品开发队伍，其产品 先后获得"中国名牌产品""国家科学技术进步二等奖"等荣誉，这使 得我国浓缩果汁在国际市场上的竞争力不断增强。感谢您对公司的支 持与关注！ 投资者关系活 动类别 √ 特定对象调研 √ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 √ 现场参观 □ 其他 形式 √ 现场 □ 电话会议 参与单位名称 中信证券、中金公司、长江证券、国联民生证券、招商证券、民生证 券、方正证券、东北证券、信达证券、华夏基金、南方基金、兴全基 金、建信养老基金、招银理财、万家基金、长城基金、华泰柏瑞、申 万宏源、安信基金、淳厚基金、太保资管、国泰海通资管、中信保诚 资管、立心基金、爱建证券资管等（排名不分先后） 时间 2025 年 5 月 23 日 ...

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Dividend Announcement - The company Yantai North Andre Juice Co., Ltd. has announced a final dividend of 2.5 RMB per 10 shares for the fiscal year ending December 31, 2024 [1] - The dividend declaration date is pending approval from shareholders [1] - The dividend will be distributed in HKD, with the exact amount and exchange rate to be announced later [1] Key Dates - Ex-dividend date is set for June 25, 2025 [1] - The last date for submitting share transfer documents to qualify for the dividend is June 27, 2025, to July 2, 2025 [1] - Record date for the dividend is July 2, 2025, and the payment date is August 6, 2025 [1] Tax Information - A withholding tax rate of 10% applies to non-resident enterprises and non-individual residents holding shares [2] - For mainland individual investors holding H-shares through Stock Connect, a withholding tax rate of 20% will be applied [2]

ANDRE Yantai North Andre Juice Co., Ltd. * 02218 公告 董事會專門委員會組成之變動 茲提述烟台北方安德利果汁股份有限公司（「本公司」）日期為二零二五年四月二十五日的 通函（「通函」）及二零二五年五月十六日的年度股東大會投票表決結果公告，內容有關（其 中包括）王常青先生已獲委任為本公司獨立非執行董事。除文義另有所指外，本公告所用 詞彙與通函所界定者具相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 烟台北方安德利果汁股份有限公司 董事長 王安 中國烟台，二零二五年五月二十日 於本公告日期，本公司執行董事為王安先生、張輝先生、王萌女士及王艷輝先生，非執 行董事為劉宗宜先生及張偉先生，獨立非執行董事為龔凡先生、王雁女士及王常青先 生。 * 僅供識別 本公司謹此宣佈，王常青先生已獲委任為本公司審計委員會成員、提名委員會成員及薪 酬與考核委員會成員，自二零二五年五月二十日起生效。 承董事會命 ...

董事名單與其角色和職能 烟台北方安德利果汁股份有限公司董事會(「董事會」)成員與其角色和職能載列如下: 龔凡先生 王雁女士 王常青先生 董事會成立了四個委員會, 其成員載列如下: 審計委員會： 執行董事： 王安先生(董事長) 張輝先生 王萌女士 王艷輝先生 非執行董事： 劉宗宜先生 張偉先生 獨立非執行董事： 龔凡先生(主任) 王雁女士 王常青先生 薪酬與考核委員會： 龔凡先生(主任) 張偉先生 王常青先生 提名委員會： 龔凡先生(主任) 王安先生 王常青先生 戰略委員會： 王安先生(主任) 龔凡先生 張偉先生 中國烟台，二零二五年五月二十日 * 僅供識別 ...

EF001 免責聲明 EF001 | | 股東類型 | 稅率 | 有關代預扣所得稅之更多補充 | | --- | --- | --- | --- | | | | | （如適用） | | 非居民企業 | | | | | （非中國內地登記地址） | | 10% | 任何以非個人股東名義，包括以香 | | | | | 港中央結算（代理人）有限公司、 | | | | | 其他代理人或受托人、以及其他組 | | | | | 織及團體名義登記的股份皆被視為 | | | | | 由非居民企業股東持有，因此本公 | | | | | 司將代扣代繳10%的企業所得稅。 | | 非個人居民 | | | | | （非中國內地登記地址） | | 10% | 本公司在向香港居民的H股個人股 | | | | | 東派發2023年末期股息時，將按 | | | | | 10%的稅率代扣代繳個人所得稅， | | | | | 但稅務法規、相關稅收協定或通知 | | | | | 另有規定的，將按相關規定及稅收 | | | | | 徵管要求具體辦理。 | | 通過滬港通或深港通持有本公 | | 20% | 對內地個人投資者通過滬港通或深 | | 司H ...

Group 1 - The company announced the termination of its plan to issue A-shares to specific investors for the year 2024, as approved in the first meeting of the ninth board of directors and the ninth supervisory board on May 20, 2025 [1] - The termination was due to the securities service institution hired for the issuance no longer meeting the requirements for the simplified procedure, unrelated to the company or the issuance itself [1] - The company stated that this decision is a prudent choice based on actual circumstances and will not adversely affect its operations or the interests of shareholders, especially minority shareholders [1] Group 2 - The company had previously disclosed a plan to raise a total of no more than 30 million yuan (approximately 4.5 million USD) through the simplified procedure, which would be used for various projects including a production line for decolorized and deacidified concentrated juice [2] - The company was listed on the Shanghai Stock Exchange on September 18, 2020, with an initial public offering of 20 million shares at a price of 7.60 yuan per share, raising a total of 15.2 million yuan (approximately 2.3 million USD) [2] - The issuance costs amounted to 3.05 million yuan (approximately 0.46 million USD), with the underwriting and sponsorship fees to Huaying Securities being 2.30358 million yuan (approximately 0.35 million USD) [3] Group 3 - The company's actual controller is Wang An and Wang Meng, a father-daughter duo, with Wang Meng holding Canadian nationality [4]